The expression and function of the serotonin transporter (SERT) is important in the regulation of mood and emotion. Determination of SERT alterations in physiological and pathological states is essential for understanding the role of SERT in mood regulation, and in the etiology and therapy of psychiatric disorders. Two SERT ligands, AFM ( The function of the serotonin transporter (SERT) is to reuptake 5-HT from synaptic cleft back into serotonin nerve terminals for enzymatic degradation or recycling. By doing so, SERT controls the concentration of 5-HT in the synaptic cleft and perisynaptic regions and thus its actions at 5-HT receptors. Studies have shown that the function of SERT is important in regulation of emotional states. For example, a polymorphism in the promoter region of human SERT (5HT-TLPR) that alters the expression of SERT may be related to personality traits and to some psychiatric disorders, including depression (Lesch et al., 1996; Murphy et al., 2001; Caspi et al., 2003) . In addition, SERT is the target of serotonin reuptake inhibitors (SRIs), a group of widely used antidepressants (Owens, 1997). Therefore, in vivo studies of SERT may help us to understand its role in normal physiology and in pathological states.
The function of the serotonin transporter (SERT) is to reuptake 5-HT from synaptic cleft back into serotonin nerve terminals for enzymatic degradation or recycling. By doing so, SERT controls the concentration of 5-HT in the synaptic cleft and perisynaptic regions and thus its actions at 5-HT receptors. Studies have shown that the function of SERT is important in regulation of emotional states. For example, a polymorphism in the promoter region of human SERT (5HT-TLPR) that alters the expression of SERT may be related to personality traits and to some psychiatric disorders, including depression (Lesch et al., 1996; Murphy et al., 2001; Caspi et al., 2003) . In addition, SERT is the target of serotonin reuptake inhibitors (SRIs), a group of widely used antidepressants (Owens, 1997) . Therefore, in vivo studies of SERT may help us to understand its role in normal physiology and in pathological states.
Positron emission tomography (PET) allows the in vivo measurement of the density and distribution of a target protein (Mountz et al., 2002; Parsey and Mann, 2003) . Clear interpre-tation of PET imaging results depends, therefore, on the selectivity of the probe for its target protein. 2-[2-(Dimethylaminomethylphenylthio)]-5-fluoromethylphenylamine (AFM) and 3-amino-4-[2-(dimethylaminomethylphenylthio) ]benzonitrile (DASB) are new compounds recently developed as SERT ligands Huang et al., 2002b; Ginovart et al., 2003) . Although they have been used in PET scans of humans and monkeys, relatively little information has been reported on their pharmacological profile. Although in vitro pharmacological studies of DASB have been reported (Wilson et al., 2002) , no data are available for the pharmacological profile of AFM. In addition, Wilson et al. (2002) showed that fluoxetine (up to 1 mg/kg) did not completely block [ 11 C]DASB binding in rats (Wilson et al., 2002) . A likely reason for this incomplete blockade is that the dose of fluoxetine was not high enough to block all SERT binding sites, because complete blockade of SERT sites requires at lease 10 mg/kg fluoxetine in rats (Fuller et al., 1978) . However, it is necessary to evaluate the specificity of these two ligands. In the present studies, we used SERT knockout mice as a "clean" pharmacological state to examine the selectivity of these two PET ligands for SERT. 
Materials and Methods

Animals
Female SERT mutant mice from a 129sv/ev background (Bengel et al., 1998) were used for the autoradiographic studies. The SERT mutant mice and their SERT normal littermates were from the F9 generation and were 5 to 8 mo of age, with body weights of 25 to 35 g. In the homogenate binding studies, normal male C57/B6 mice were used. The mice were housed in groups of four to five per cage in a light-(12-h light/dark, lights on at 6:00 AM), humidity-, and temperature-controlled room. Food and water were available ad libitum. All animal procedures were approved by the National Institute of Mental Health Animal Care and Use Committee. , respectively. Citalopram, nisoxetine, 8-OH-DPAT, ketanserin, mianserin, and fenfluramine were purchased from Sigma/RBI (Natick, MA). RU 24969 and RS 102221 were purchased from Tocris (Ballwin, MO.).
Materials
Autoradiographic Studies
Preparation of Brain Sections. Female mice with intact (ϩ/ϩ), heterozygous (Ϯ), and homozygous knockout (Ϫ/Ϫ) SERT genes were decapitated. The whole brains were removed and frozen immediately in dry ice-cooled isopentane for 10 s. The brains were then placed on dry ice for 10 min until they were completely frozen. Brains were wrapped and stored at Ϫ80°C until sectioning.
The mouse brain was cut into 16-m-thick coronal sections in a cryostat. The sections were thaw-mounted onto chromalum/gelatincoated glass slides and stored at Ϫ80°C for studies within 1 month. To limit variation among the slides, each slide contained brain sections from three mice (one genotype each). Three levels of sections were collected: hippocampus (bregma Ϫ1.34 to Ϫ1.94 mm), midbrain (bregma Ϫ4.36 to Ϫ4.84 mm), and cerebellum (bregma Ϫ5.20 to 5.40 mm) according to a mouse brain atlas (Franklin and Paxinos, 1997 (2000) and Li et al. (1997) . Whole cortex or midbrain were dissected immediately after decapitation of normal mice and were stored at Ϫ80°C until use. The cortex or midbrain was homogenized in 10 ml of assay buffer (50 mM Tris-HCl, pH 7.5, containing 150 mM NaCl and 5 mM KCl) with Tissue Tearor homogenizer at top speed for about 10 s at 4°C. The homogenates were centrifuged at 35,000g for 20 min at 4°C. The pellets were resuspended to 10 ml of assay buffer and centrifuged at 35,000g for 20 min. The final pellet was resuspended in assay buffer (30 mg tissue/ml). Protein concentrations of the homogenates were determined by the Lowry assay (Lowry et al., 1951) .
For saturation studies, 50 l of tissue homogenate was incubated with [
3 H]AFM in total volume of 1 ml of assay buffer for 2 h at room temperature. Six concentrations of [ 3 H]AFM (between 0.5-15 nM for midbrain and 0.5-8 nM for cortex) were used in the assay. Nonspecific binding was defined in the presence of 10 Ϫ5 M paroxetine (which was about 50% of total binding using 0.5 nM ligands). The incubated solution was then filtered with Whatman GF/C filter paper (pretreated with 0.5 mM Tris-HCl, pH 7.4) and washed three times with 4 ml of cold 0.5 mM Tris-HCl, pH 7.4. The filter paper was counted in 5 ml of scintillation fluid (Ecolife; ICN Biomedicals, Costa Mesa, CA). The dissociation constant K d and receptor density B max were calculated by nonlinear regression using the Prism (version 4) program (GraphPad Software Inc., San Diego, CA).
For competition studies, 50 l of cortex homogenate was incubated with 2 nM [ 3 H]AFM in total volume of 1 ml of assay buffer containing 10 Ϫ12 to 10 Ϫ7 M 5-HT transporter inhibitors (paroxetine and citalopram) or 10 Ϫ10 to 10 Ϫ4 M other drugs. Nonspecific binding was defined in the presence of 10 Ϫ5 M paroxetine except that 10 Ϫ5 M citalopram was used in the competition study for paroxetine. Solutions were incubated for 2 h at room temperature and filtered as described above. K i values and Hill slopes were calculated by one-site competition nonlinear regression using the Prism program. In the case when the Hill slope was less than 1, two-site competition nonlinear regression was used to further evaluate the possibility of two binding sites. 
Results
Autoradiography
Discussion
The present results demonstrate that AFM and DASB are selective SERT ligands. Their binding can be displaced by selective serotonin reuptake inhibitors but not by drugs selective for the other two major monoamine transporters (dopamine and norepinephrine). The K d of AFM in the midbrain observed in the present study was consistent with its K i value determined by displacement of AFM binding to [
3 H]paroxetine sites (Huang et al., 2002a) . Furthermore, AFM was 3 H]AFM (1 nM) was used in the assay (total). Nonspecific binding (NSB) was defined in the presence of 10 Ϫ5 M paroxetine. The nonspecific binding sites were about 5 to 50% of total binding in various brain regions. CA1, CA1 region of hippocampus; CL, locus ceruleus; CTX, cortex; DR (MB), dorsal raphe in the midbrain section; DR (cer), dorsal raphe in the cerebellum section; LPTh, lateral posterior thalamus; MR, median raphe; PH, posterior hypothalamic area; and PV, paraventricular thalamus.
Fig. 2. Autoradiography of [
3 H]DASB binding to coronal brain sections of SERT knockout mice. Left, wild-type SERT mice (ϩ/ϩ); middle, heterozygous SERT knockout mice (Ϯ); and right, homozygous SERT knockout mice (Ϫ/Ϫ). [ 3 H]DASB (1 nM) was used in the assay (total). Nonspecific binding (NSB) was defined in the presence of 10 Ϫ5 M paroxetine. The nonspecific binding sites were about 10 to 50% of total binding in various brain regions. In the present study, we used SERT knockout mice as a tool to study the selectivity of AFM and DASB. SERT knockout mice were created by disrupting the second exon of the 5-HT transporter gene. Thus, SERT knockout mice do not express intact 5-HT transporters and cannot bind SERT ligands, including RTI-55 and citalopram (Bengel et al., 1998 ]DASB used in the present study is at least 10 times higher than that achieved in a typical PET scan, suggesting that the in vivo binding sites of these ligands are predominantly SERT.
SERT binds several types of antidepressants, including SRIs, such as paroxetine and citalopram, and some of tricyclic antidepressants, such as imipramine and clomipramine. Among these ligands, SRIs have higher affinity and greater selectivity than tricyclic antidepressants (Levy and Van de Kar, 1992; Lane and Baker, 1999) . [ 3 H]Imipramine has both high-and low-affinity binding sites, whereas [ 3 H]paroxetine has only one binding site in rat brain (Hrdina, 1987; Hrdina et al., 1990 (Hrdina et al., 1990 ). In addition, competition studies showed that both citalopram and paroxetine have a high potency to compete with [ 3 H]AFM (Table 2 ; Fig. 4 ). The present data were also consistent with others indicating that the affinity of paroxetine is about 10 times higher than that of citalopram (Wong et al., 1995) . These results suggest that AFM and DASB are highly selective SERT ligands.
Several monoamine transporter inhibitors have high affinity for SERT, the dopamine transporter (DAT), and/or the norepinephrine transporter (NET). For example, cocaine and several its analogs, such as RTI-55, have high affinity for SERT and dopamine transporters (Boja et al., 1992; Silverthom et al., 1994; Shearman et al., 1996) . Duloxetine has high affinity for both SERT and NET (Fuller et al., 1994; Bymaster et al., 2001) . Therefore, it is important to evaluate the affinity of new ligands for DAT and NET. We expected if these compounds have high affinity for DAT and NET, we should detect binding sites in substantia nigra (DAT) and locus ceruleus (NET) of SERT Ϫ/Ϫ mice, which have intact DAT and NET. As shown in Figs. 1 Fig. 3 ). These results suggest that AFM and DASB bind selectively to 5-HT transporters, but not to dopamine or norepinephrine transporters.
Some SRIs, such as fluoxetine, have relative high affinity for 5-HT 2C and/or 5-HT 2A receptors (Wong et al., 1995; Palvimaki et al., 1996) . We examined the affinities of AFM for 5-HT 1A , 5-HT 1B , 5-HT 2A , and 5-HT 2C receptors. The K i values of all the agonists and antagonists tested in the present studies are at least 100 times higher than those for SRIs (Table 2 ; Fig. 5 ). Unlike fluoxetine, AFM has almost undetectable binding to 5-HT 2A receptors (K i for ketanserin is undetectable) and very low affinity for 5-HT 2C receptors (K i of RS 102221 is 1.7 ϫ 10 Ϫ5 M). The present results showed that the Hill slopes for citalopram and paroxetine competition curve were less than 1. In addition, the K d value for [ 3 H]AFM binding in the cortex was higher than that in the midbrain. Furthermore, the [ 3 H]AFM binding sites in the cortex were much lower than that in the dorsal raphe in the autoradiographic assay (1 nM AFM), whereas in the homogenate binding studies, the B max of [ 3 H]AFM binding in the cortex was much higher than that in the midbrain. Although the higher B max of [ 3 H]AFM binding in the cortex than that in the midbrain determined by homogenate assay could be due to that high SERT density in the raphe nuclei are diluted by their surround tissue that has low SERT, the different between the two regions is too high to be explained by the dilution effect. Thus, these data suggest that Fenfluramine is an amphetamine derivative and functions as a 5-HT releaser. Its action requires 5-HT transporters and can be blocked by SRIs (Baumann et al., 1998; Rothman and Baumann, 2002) . Two mechanisms may be involved in fenfluramine-induced 5-HT release. At low concentrations, fenfluramine stimulates a Ca 2ϩ -dependent 5-HT release, suggesting that this 5-HT release is mediated by an exocytotic process (Cinquanta et al., 1997a) . At high concentrations, fenfluramine-induced 5-HT release is mediated by a Ca 2ϩ -independent process in which fenfluramine may exchange with 5-HT through SERT (Levi and Raiteri, 1993; Rudnick and Wall, 1993; Cinquanta et al., 1997b) . However, it is unclear whether the action of fenfluramine requires binding to SERT at SRI binding sites. We performed a competition study using fenfluramine to displace [ 3 H]AFM binding. Our results showed that fenfluramine has little capacity to bind to 5-HT transporter, at least at the site labeled with [ 3 H]AFM. It was reported that amphetamine derivatives, such as p-chloroamphetamine and 3,4-methylenedioxymeth- amphetamine, bind to SERT with an affinity about 10 Ϫ7 M. (Battaglia et al., 1988; Rudnick and Wall, 1992) . It is interesting that fenfluramine has a low affinity for SERT. However, we cannot rule out that fenfluramine binds to SERT through other sites rather than AFM binding sites. Further studies are required to clarify this possibility.
In the present studies, we demonstrated that AFM and DASB selectively bind to SERT. AFM has very low affinity for norepinephrine transporters and dopamine transporters. The affinities of AFM for 5-HT 1A , 5-HT 1B , 5-HT 2A , and 5-HT 2C receptors are much lower than those of SRIs. It will be interesting to know what are the pharmacological effects of these ligands. For example, are they SERT inhibitors or enhancers? Do they have the potential to be used as antidepressants? Future studies should be pursued to address these questions.
In conclusion, the present results demonstrate that AFM and DASB are selective ligands for SERT in mouse brain and offer supportive data validating their use as PET ligands for SERT in humans and other species. Furthermore, several questions for future studies are raised from the present results, which will help us to understand the pharmacological properties of these ligands.
